A ‘breadth of protection:’ Novavax’s newly-approved COVID vaccine arms the U.S. with a new weapon against Omicron BA.5 subvariant

This post was originally published on this site

https://content.fortune.com/wp-content/uploads/2022/07/GettyImages-1241112231-e1657772286610.jpg



Novavax’s FDA-approved COVID vaccine is well-suited to fight Omicron BA.5 | Fortune